Reckitt Benckiser to spin out US pharma arm


Consumer health firm Reckitt–Benckiser plans to spin off its US pharmaceutical division, whose primary product is heroin-substitute Suboxone (buprenorphine and naloxone) for treating addiction.

Suboxone’s patent protection has expired, and generic competition is eroding the drug’s sales and market share. With Reckitt increasingly focusing on over-the-counter and consumer products, the company has decided that the best option is to divest the business as a separate company, specialising in addiction. Reckitt expects the spin-off to be completed in the next 12 months.


Related Content

Reckitt steps into Schiff deal

19 November 2012 Business

news image

Higher bid could sink Bayer's $1.2bn attempt to buy vitamins and nutritional supplements company

The pain killer

13 November 2013 Jobs Profile (Personal)

news image

Life is pretty painless working in Reckitt Benckiser's Nurofen team, Sarah Houlton learns

Most Read

UC Davis chemist sentenced to four years over explosion

19 November 2014 News and Analysis

news image

Postdoc sentenced over attempt to make explosive device and reckless disposal of hazardous waste

Grad student blamed for research misconduct at Utah

13 November 2014 News and Analysis

news image

Two papers have been retracted due to image falsification at the University of Utah

Most Commented

Beetle behind breath test for bank notes

17 November 2014 Research

news image

Photonic crystal inks inspired by longhorn beetle could help to fight counterfeiting

Bayer wins race to buy Merck & Co consumer care

9 May 2014 Business

news image

$14bn deal will make Aspirin inventor the number two over-the-counter healthcare company